Government fund of funds
Development institute of the Russian Federation


Outcomes of RVC business breakfast: "State as LP: pros and cons"
14 февраля РВК провела бизнес-завтрак с участием партнеров и инвесторов ведущих российских венчурных фондов. Эксперты обсудили возможные преимущества и риски работы с государственным капиталом, а также детально ознакомились с параметрами открытого конкурса на поиск управляющего товарища венчурного фонда НТИ.
RVC announces the beginning of the selection of the managing partner (MP) for the NTI venture fund. The fund will be established in the form of an investment partnership for a period of 10 years, the investment period will be 5 years. The operator of the selection procedure will be RVC Infrafund, which in future will become a mere fellow investor of the fund created in accordance with the draft of the National Technology Initiative "Venture Support for the Growth of NTI Companies".
According to Firrma's annual activity rating of Russian venture funds, the strategic partners of which are RVC and EY, 2017 saw three times as many established venture capital funds (11) compared to the previous year (4).
American biotechnology company OncoTartis Inc., which is developing a new class of antitumor drugs, raised $ 6 million from two investors. The funds will be used to conduct Phase I of clinical trials for OT-82, a drug for resistant forms of acute leukemia.
RVC, Roscosmos and VEB Innovations announced establishment of a venture fund in form of Investment Partnership Agreement. The agreement of intent was signed by Alexander Povalko, the CEO of RVC, Anton Zhiganov, executive director for business development and commercialization at Roskosmos and Kirill Bulatov, CEO of VEB Innovations LLC.
The interdepartmental working group under the presidium of the Council for Economic Modernization and Innovative Development approved a grant of 244 million rubles for the implementation of SKYF project, which is an unmanned aerial carrier platform for cargo transportation and agricultural aviation.
The BioFund of RVC (Biopharmaceutical Investments of RVC LLC) increased its stake, from 54.44% to 69.48%, in PrimeBioMed, a research and production company which accumulates achievements in the field of molecular and cellular diagnostics.

1 2 3 4 5 ... 7 Next
News for 2018: January February March April May
News archive: 2017 2016 2015 2014 2013 2012 2011

Search by name:

Search by date:

Select date in calendar
Select date in calendar